Daniel Krause, DO
Internal Medicine · Wausau, WINPI 1457768327
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,360 of the $3,579 with a category attached, or 65.9%. 18 manufacturers reported payments, led by Heartflow, Inc. at 51.7% of the total. Reporting peaked in 2023 at $2,154 and has fallen 84.7% since, to $330 in 2025. Among internal medicine clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $68.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- AstraZeneca$262
- Inari Medical, Inc.$217
- Amgen$209
- Johnson & Johnson$185
- Boehringer Ingelheim$143
- plus $713 from 12 others
Across 3 payments — averaging $12,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$38K
What the payments were for
- Consulting fees$993%
- Travel & lodging$1,11931%
- Food & beverage$2,36066%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 15 | $1,850 |
| AstraZeneca | 4 | $262 |
| Inari Medical, Inc. | 2 | $217 |
| Amgen | 5 | $209 |
| Johnson & Johnson | 5 | $185 |
| Boehringer Ingelheim | 2 | $143 |
| Siemens Medical Solutions USA, Inc. | 2 | $136 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $114 |
| Novartis | 5 | $113 |
| Penumbra, Inc. | 1 | $104 |
| Abbott | 1 | $93 |
| Pfizer | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Novo Nordisk | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Medtronic | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$1,401
- JARDIANCE$125
- FLOWTRIEVER CATHETER, S$123
- CT THROMBECTOMY SYSTEM KIT$123
- XARELTO$107
- FARXIGA$105
- Indigo System$104
- Repatha$101
How this compares
$3,579 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 378 | $407,909 |
| VyndamaxTafamidis | 11 | $254,167 |
| EntrestoSacubitril/Valsartan | 114 | $155,494 |
| JardianceEmpagliflozin | 169 | $142,478 |
| XareltoRivaroxaban | 106 | $121,602 |
| Repatha SureclickEvolocumab | 57 | $52,337 |
| MultaqDronedarone Hcl | 19 | $32,983 |
| WegovySemaglutide | 15 | $19,267 |
| BrilintaTicagrelor | 11 | $11,158 |
| Metoprolol Succinate | 653 | $9,598 |
| FarxigaDapagliflozin Propanediol | 12 | $8,015 |
| Bumetanide | 136 | $5,699 |
| Ranolazine ErRanolazine | 34 | $5,546 |
| Potassium Chloride | 113 | $5,147 |
| Atorvastatin Calcium | 500 | $3,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $36 | $662,076389 claims |
| NovartisEntresto | $113 | $155,494114 claims |
| Boehringer IngelheimJardiance | $143 | $142,478169 claims |
| Johnson & JohnsonXarelto | $185 | $121,602106 claims |
| Novo NordiskWegovy | $24 | $19,26715 claims |
| AstraZenecaBrilinta, Farxiga | $262 | $19,17423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Wausau
- Kris LahrenWausau$5K
- Jeremiah DeptaMilwaukee$723K
- James KuplicSheboygan$201K
- Erik StilpMilwaukee$116K
- Christopher WeberGermantown$113K
- Alejandro EismaWinnebago$84K
- Hammam ShereefMilwaukee$55K
- Brian SchreiberNeenah$49K
- Kaye-Eileen WillardRacine$47K
- Haroon ZubairWauwatosa$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.